Influence of the CYP17 polymorphism on vasomotor symptoms in postmenopausal women: A pilot study

Climacteric

Volumn 14, Issue 5, 2011, Pages 537-543

  Nogueira Jr , R C ^a   Costa, A M Massad ^a   Silva, I D C G ^a   Carvalho, C Valleta ^a   Maganhin, C ^a   Baracat, E C ^b   Soares Jr , J M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CYP17; Estrogen; Hot flushes; Polymorphism

Indexed keywords

CONJUGATED ESTROGEN; CYTOCHROME P450 17; ESTROGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

5' UNTRANSLATED REGION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; ENZYME POLYMORPHISM; FEMALE; HUMAN; KUPPERMAN MENOPAUSAL INDEX; LOW DRUG DOSE; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; SELF REPORT; TREATMENT OUTCOME; VASOMOTOR DISORDER;

ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; PILOT PROJECTS; POLYMORPHISM, GENETIC; POSTMENOPAUSE; SEX HORMONE-BINDING GLOBULIN; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE; VASOMOTOR SYSTEM;

EID: 80053016905     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2010.548668     Document Type: Article

References (28)

1. Oldenhave A, Jasszmann LJ, Haspels AA, et al. Impact of climacteric on well-being: a survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772-80
2. Galhardo CL, Soares JM Jr, Simões RS, Haidar MA, Rodrigues de Lima G, Baracat EC. Estrogen effects on the vaginal pH, fl ora and cytology in late postmenopause after a long period without hormone therapy. Clin Exp Obstet Gynecol 2006;33:85-9
3. Avis NE, Crawford S, Stellato R, Longcope C. Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric 2001;4:243-9
4. Joffe H, Hall JE, Soares CN, et al. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002;9:392-8
5. Whiteman MK, Staropoli CA, Benedict JC, et al. Risk factor for hot fl ashes in midlife women. J Womens Health (Larchmt) 2003; 12:459-72
6. Kronemberg F, Downey JA. Thermoregulatory physiology of menopausal hot fl ashes: a review. Can J Physiol Pharmacol 1987; 65:1312-24
7. Freedman RR. Hot fl ashes revisited. Menopause 2000;7:3-4
8. Freedman RR. Physiology of hot fl ashes. Am J Hum Biol 2001; 13:453-64
9. Silva NL, Boulant JA. Effects of testosterone, estradiol and temperature on neurons in preoptic tissues slices. Am J Physiol 1986;250:R625-32
10. Altura BM. Sex as a factor infl uencing the responsiveness of arterioles to catecholamines. Eur J Pharmacol 1972;20:261-5
11. Freedman RR, Blacker CM. Estrogen raises the sweating threshold in postmenopausal women with hot fl ashes. Fertil Steril 2002; 77:487-90
12. Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes envolved in oestrogen biosynthesis and metabolism. Mut Res 2003;544: 9-41
13. Huber JC, Schneeberger C, Tempfer CB. Genetic modeling of the estrogen metabolism as a risk factor of hormone-dependent disorders. Maturitas 2002;42:1-12
14. Erlik Y, Meldrum DR, Judd HL. Estrogen level in postmenopausal women with hot fl ashes. Obstet Gynecol 1982; 59:403-4
15. Carey AH, Waterworth D, Patel K, et al. Polycystic ovaries and premature male pattern baldness are associated with an allele of the steroid metaboli m gene CYP17. Hum Mol Genet 1994; 3:1873-6
16. Sharp L, Cardy AH, Cotton SC, et al. CYP17 gene polymorphisms: prevalence and association with hormone levels and related factors. A huge review. Am J Epidemiol 2004; 160:729-40
17. Malacara JM, Perez-Luque EL, Martinez-Garza S, et al. The relationship of estrogen receptor-polymorphism with symptoms and other characteristics in post-menopausal women. Maturitas 2004;49:163-9
18. Visvanathan K, Gallicchio L, Schilling C, et al. Cytochrome gene polymorphisms, serum estrogens, and hot fl ushes in midlife women. Obstet Gynecol 2005;106:1372-81
19. Kang D. Genetic polymorphisims and cancer susceptibility of breast cancer in Korean women. J Biochem Mol Biol 2003;36: 28-34
20. Patriarca MT, Rodrigues de Lima G, Stavale JN, et al. Ultrasonographic and morphological studies of the postmeno pausal endometrium using unopposed estrogen replacement therapy with regular pause. A prospective preliminary study. Eur J Obstet Ginecol Reprod Biol 2001;98:119-23
21. Fardellone P. Predicting the fracture risk in 2008. Joint Bone Spine 2008;75:661-4
22. Fay MP, Proschan MA. Wilcoxon-Mann-Whitney or t-test? On assumptions for hypothesis tests and multiple interpretations of decision rules. Stat Surv 2010;4:1-39
23. Miyoshi Y, Noguchi S. Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer in Japanese women. Biomed Pharmacother 2003;57:471-81
24. Haiman CA, Hankinson SE, Spiegelman D, et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999;59:1015-20
25. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002:94:606-16
26. Tworoger S, Chubak J, Aiello E, et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol, Biomarkers Prevention 2004;13:94-101
27. Jernstrom H, Vesprini D, Bradlow HL, et al. Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 2001;93:554-5
28. Feigelson HS, McKean-Cowdin R, Pike MC, et al. Cytochrome P450c17 alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res 1999;59:3908-10